Skip to main content
. 2021 Dec 13;156(2):317–327. doi: 10.1007/s11060-021-03912-6

Fig. 2.

Fig. 2

MGMT as a marker for survival and disease progression in glioblastoma and IDHwt astrocytoma with pTERTmut. A/C Kaplan–Meier estimates of overall survival in glioblastoma and IDHwt astrocytoma with pTERTmut treated with any form of radio-/chemotherapy. Curves are displayed for patients with > 18 methylated CpG sites (straight lines) and ≤ 18 methylated CpG sites (dottes lines) B/D Kaplan–Meier estimates of radiographic progression-free survival in glioblastoma and IDHwt astrocytoma with pTERTmut treated with any form of radio-/chemotherapy. Curves are displayed for patients with > 18 methylated CpG sites (straight lines) and ≤ 18 methylated CpG sites (dottes lines). E/F Kaplan–Meier estimates of overall survival (E) and radiographic progression-free survival (F) in IDHwt astrocytoma with pTERTmut treated with first-line radiochemotherapy or chemotherapy. Curves are displayed for patients with > 18 methylated CpG sites (straight lines) and ≤ 18 methylated CpG sites (dottes lines). Tick marks indicate censored patients. B therapy: brachytherapy; C therapy: chemotherapy; CpG: Cytosine-Guanine dinucleotide; IDHwt: isocitrate dehydrogenase 1/2 wildtype; pTERTmut: TERT promotor mutation; R therapy: radiotherapy; RC therapy: radiochemotherapy